122 related articles for article (PubMed ID: 35100339)
21. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
[TBL] [Abstract][Full Text] [Related]
22. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.
Anguille S; Van de Velde AL; Smits EL; Van Tendeloo VF; Juliusson G; Cools N; Nijs G; Stein B; Lion E; Van Driessche A; Vandenbosch I; Verlinden A; Gadisseur AP; Schroyens WA; Muylle L; Vermeulen K; Maes MB; Deiteren K; Malfait R; Gostick E; Lammens M; Couttenye MM; Jorens P; Goossens H; Price DA; Ladell K; Oka Y; Fujiki F; Oji Y; Sugiyama H; Berneman ZN
Blood; 2017 Oct; 130(15):1713-1721. PubMed ID: 28830889
[TBL] [Abstract][Full Text] [Related]
24. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
25. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.
Romano E; Rossi M; Ratzinger G; de Cos MA; Chung DJ; Panageas KS; Wolchok JD; Houghton AN; Chapman PB; Heller G; Yuan J; Young JW
Clin Cancer Res; 2011 Apr; 17(7):1984-97. PubMed ID: 21355077
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.
Kyte JA; Mu L; Aamdal S; Kvalheim G; Dueland S; Hauser M; Gullestad HP; Ryder T; Lislerud K; Hammerstad H; Gaudernack G
Cancer Gene Ther; 2006 Oct; 13(10):905-18. PubMed ID: 16710345
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M
Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694
[TBL] [Abstract][Full Text] [Related]
28. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
Nooka AK; Wang ML; Yee AJ; Kaufman JL; Bae J; Peterkin D; Richardson PG; Raje NS
JAMA Oncol; 2018 Dec; 4(12):e183267. PubMed ID: 30128502
[TBL] [Abstract][Full Text] [Related]
30. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
[TBL] [Abstract][Full Text] [Related]
31. Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy.
Chung DJ; Romano E; Pronschinske KB; Shyer JA; Mennecozzi M; St Angelo ET; Young JW
J Transl Med; 2013 Jul; 11():166. PubMed ID: 23837662
[TBL] [Abstract][Full Text] [Related]
32. Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation.
Takahashi S; Minnie SA; Ensbey KS; Schmidt CR; Sekiguchi T; Legg SRW; Zhang P; Koyama M; Olver SD; Collinge AD; Keshmiri S; Comstock ML; Varelias A; Green DJ; Hill GR
Blood; 2024 Apr; 143(16):1656-1669. PubMed ID: 38295333
[TBL] [Abstract][Full Text] [Related]
33. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
35. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
Holstein SA; Jung SH; Richardson PG; Hofmeister CC; Hurd DD; Hassoun H; Giralt S; Stadtmauer EA; Weisdorf DJ; Vij R; Moreb JS; Callander NS; van Besien K; Gentile TG; Isola L; Maziarz RT; Bashey A; Landau H; Martin T; Qazilbash MH; Rodriguez C; McClune B; Schlossman RL; Smith SE; Hars V; Owzar K; Jiang C; Boyd M; Schultz C; Wilson M; Hari P; Pasquini MC; Horowitz MM; Shea TC; Devine SM; Linker C; Anderson KC; McCarthy PL
Lancet Haematol; 2017 Sep; 4(9):e431-e442. PubMed ID: 28826616
[TBL] [Abstract][Full Text] [Related]
36. Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
Garcia-Marquez MA; Shimabukuro-Vornhagen A; Theurich S; von Bergwelt-Baildon M
Immunotherapy; 2013 Oct; 5(10):1039-42. PubMed ID: 24088074
[TBL] [Abstract][Full Text] [Related]
37. Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.
Parrish C; Morris CTCM; Williams CD; Cairns DA; Cavenagh J; Snowden JA; Ashcroft J; Cavet J; Hunter H; Bird JM; Chalmers A; Brown JM; Yong K; Schey S; Chown S; Cook G;
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1009-1016. PubMed ID: 26827659
[TBL] [Abstract][Full Text] [Related]
38. An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination.
Brabants E; Heyns K; De Smet S; Devreker P; Ingels J; De Cabooter N; Debacker V; Dullaers M; VAN Meerbeeck JP; Vandekerckhove B; Vermaelen KY
Cytotherapy; 2018 Sep; 20(9):1164-1181. PubMed ID: 30122654
[TBL] [Abstract][Full Text] [Related]
39. [Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment].
Ning X; Wei X; Guo X; Wei Q; Huang F; Fan Z; Xu N; Sun J; Feng R; Liu Q; Wei Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(9):1420-1425. PubMed ID: 34658359
[TBL] [Abstract][Full Text] [Related]
40. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
